drugset / Trial / NCT01003184

Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes

NCT01003184

Phase 3 Completed 222 enrolled AstraZeneca Eli Lilly and Company · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the effects of exenatide once weekly (QW) and insulin detemir with respect to glycemic control, body weight, lipids, safety, tolerability, and patient reported outcomes.

Timeline

Start
2009-10
Primary completion
2011-07
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 2 mg Subcutaneous
Comparator insulin detemir Protein / enzyme biologic Subcutaneous